Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd has demonstrated a positive financial outlook due to the successful Phase 3 trials of its drug candidates, specifically brepocitinib, which showcases consistent efficacy in treating dermatomyositis compared to existing therapies with cumbersome infusion regimens. The company has increased revenue estimates for its candidate IMVT-1402, particularly in the competitive landscape of Graves' disease, which could further enhance its market positioning. Additionally, the promising results from its pipeline, including the unique disease-modifying potential of batoclimab, underscore Roivant's capability to provide innovative treatments and capture significant market share in the biopharmaceutical sector.

Bears say

Roivant Sciences faces significant challenges in its clinical development pipeline, evidenced by the failure of key drug candidates such as brepocitinib in multiple indications, which raises concerns about the overall effectiveness and viability of its product offerings. Additionally, the ongoing complexities regarding off-target effects from certain drug mechanisms indicate potential risks that could impair therapeutic outcomes, further complicating the company's position in the competitive biopharmaceutical landscape. Furthermore, the high dependency on chronic steroid use in treating unmet medical needs reflects deeper issues within their treatment approaches, signaling that the company may struggle to capture market share in the evolving healthcare sector.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.